Equibles does not estimate personal net worth.
Get an email with a short summary when SeaStar Medical Holding Corp publishes a filing, an earnings call transcript or a press release.
Get ICU alertsEric Schlorff is recorded as CFO at SeaStar Medical Holding Corp (ICU) since August 19, 2025, Board Member at SeaStar Medical Holding Corp (ICU) since January 1, 2019 and CEO at SeaStar Medical Holding Corp (ICU). The newest filing on record that lists Eric Schlorff as CEO and Board Member at SeaStar Medical Holding Corp (ICU) is dated April 29, 2026. SeaStar Medical Holding Corp reported in an 8-K filed August 19, 2025 that Eric Schlorff was appointed principal financial officer, effective August 19, 2025. SeaStar Medical Holding Corp reported in an 8-K filed August 19, 2025 that Eric Schlorff was appointed interim Chief Financial Officer and Treasurer, effective August 19, 2025. The proxy statement of SeaStar Medical Holding Corp reports total compensation of $406,500 for Eric Schlorff in fiscal 2025, including a base salary of $406,500. Disclosed compensation is on record for 5 fiscal years. Eric Schlorff has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for SeaStar Medical Holding Corp on August 12, 2026. SeaStar Medical Holding Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at SeaStar Medical Holding Corp includes Jennifer A. Baird (Chairman and Board Member), David Green (CFO), Michael Messinger (CFO) and 4 others.
“On August 19, 2025, the Board appointed Eric Schlorff, the Company's Chief Executive Officer, as the Company's principal financial officer, interim Chief Financial Officer and Treasurer, while the Company conducts a search for a permanent replacement.”
“On August 19, 2025, the Board appointed Eric Schlorff, the Company's Chief Executive Officer, as the Company's principal financial officer, interim Chief Financial Officer and Treasurer, while the Company conducts a search for a permanent replacement.”
“We are very pleased with our progress this quarter. Our pediatric AKI market penetration and continued strong Quell Immune revenue growth bodes well for our future potential opportunity in the adult AKI market that is 50 times larger than the pediatric market in the United States.”
“Well, I will take that back to our team and we can we definitely can discuss that.”
“Since the beginning of the third quarter, we advanced our business on several fronts that we believe position us well for our future growth.”
“We are excited to share with you our achievements over the past year, and more importantly, our future plans and our passion for what we are doing here at C-Star Medical.”
2025-08-19–present
2025-08-19–present
2019-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, CFO, Board Member
2019-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | SeaStar Medical Holding Corp (ICU) | Chief Executive Officer | $406,500 | $406,500 |
| 2024 | SeaStar Medical Holding Corp (ICU) | Chief Executive Officer | $420,000 | $562,350 |
| 2023 | SeaStar Medical Holding Corp (ICU) | Chief Executive Officer | $420,000 | $637,960 |
| 2022 | SeaStar Medical Holding Corp (ICU) | Chief Executive Officer | $320,000 | $2,245,260 |
| 2021 | SeaStar Medical Holding Corp (ICU) | Chief Executive Officer | $300,000 | $322,500 |
